Headerlogotextwithshieldsshadowed
Dan Duda
Director of Translational Research in GI Radiation Oncology
Duda Lab

Duda Lab Research

Duda_HMS_CV.pdf

TARGETING MECHANISMS OF TREATMENT RESISTANCE IN HEPATO-BILIARY-PANCREATIC (HBP) MALIGNANCIES AND METASTATIC DISEASES

The research of Dr. Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 

1) local tumor progression (in liver cancers) and metastatic tumor progression (in other gastrointestinal cancers and in prostate and breast malignancies), and 

2) treatment resistance in advanced cancers. 

The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies. 

His basic and translational research efforts are currently supported by grants from the US Department of Defense Peer-Reviewed Cancer Research Program, National Cancer Institute, The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, and by several partnerships with the Industry (Bayer, BMS and Exelixis). 

Dr. Duda has authored over 200 publications so far, of which 127 are original reports. He has been invited to present his results at nearly 200 local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures. For his work, Dr. Duda received several awards, including from the American Association for Cancer Research, Cancer Research Institute, International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), MGH and the Granara-Skerry Trust for Pancreatic Cancer Research. He is a Honorary Member of the Academy of Medical Sciences of Romania since 2012. 

Dr. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, he pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH and Harvard Medical School in Boston. He became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012. In 2016, he was appointed as the Director of Translational Research in Gastrointestinal Radiation Oncology at MGH. He has been active internationally, and is currently serving as the Secretary General of the IASGO since 2015. He is a member of the AASLD Liver Fibrosis Special Interest Group. He has also been serving as a panel member for multiple scientific expert/grant review meetings worldwide since 2009, including as a permanent member of the US NCI DMP, ACS TBG, and Belgium FWO Med4 sections. He currently serves as the Chair of the FWO Med4 panel.

Dr. Duda is teaching tumor biology and translational oncology through daily supervision of postdoctoral research fellows, and graduate and undergraduate students. In the past fifteen years, he has been teaching in IASGO Postgraduate Courses in USA, Asia, Europe, Asia and South America, nationally in ASTRO, ESTRO, and RTOG translational meetings for residents and clinicians, and locally in the MIT-HMS HST Program (2005– ) and the MGH-Chinese Oncologist Visiting Program. He is coordinating a research exchange student program with University of Muenster, Germany (2015– ), and is directing the yearly Methods in Bioengineering course at MGH (2004– ). (For more information, see full CV above.) 


Duda Lab Careers

Postdoctoral Fellow

Investigator: Duda, Dan
Date Posted: 2013-08-28
Description
The Steele Laboratory is currently seeking postdoctoral applicants with expertise in molecular biology and cell biology. The project requires a motivated, independent researcher to carry out a project aimed at understanding the molecular underpinnings of liver cancer progression depending on the etiology, as well as of the differential responses to standard therapies.
Requirements
Applicants should send a CV, career statement and three letters of reference to: Dan G. Duda, DMD, PhD Associate Professor Massachusetts General Hospital & Harvard Medical School 100 Blossom Street, Cox Building 734, Boston, MA 02114 duda@steele.mgh.harvard.edu

Selected Publications (from total of 191)

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG
Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Hepatology. 2019;:ePub - PMID: 31378984 - DOI: 10.1002/hep.30889
Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol. 2018;2:22 - PMID: 30374460 - PMCID: PMC6194077 - DOI: 10.1038/s41698-018-0065-y
Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov L, Gordan R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017;7(10):1116-1135 - PMID: 28667006 - PMCID: PMC5628134 - DOI: 10.1158/2159-8290.CD-17-0368
Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Sci Rep. 2017;7:44123 - PMID: 28276530 - PMCID: PMC5343435 - DOI: 10.1038/srep44123
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Cancer. 2017;123(11):1979-1988 - PMID: 28192597 - PMCID: PMC5444988 - DOI: 10.1002/cncr.30571
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Oncologist. 2016;22(1):25-32 - PMID: 27789775 - PMCID: PMC5313267 - DOI: 10.1634/theoncologist.2016-0229
Popp I, Grosu AL, Niedermann G, Duda DG
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
Radiother Oncol. 2016;120(2):185-94 - PMID: 27495145 - DOI: 10.1016/j.radonc.2016.07.013
Hato T, Zhu AX, Duda DG
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313 - PMID: 26865127 - PMCID: PMC5619018 - DOI: 10.2217/imt.15.126
Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304 - DOI: 10.1073/pnas.1421632111
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180 - DOI: 10.1016/j.ijrobp.2014.03.034
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG
Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Hepatology. 2013;59(4):1435-47 - PMID: 24242874 - PMCID: PMC3966948 - DOI: 10.1002/hep.26790
Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 2013;45(12):1474-8 - PMID: 24185513 - DOI: 10.1038/ng.2806
Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, Jackson McCleary N, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG
Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423 - DOI: 10.1158/1078-0432.CCR-12-3041
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107
14